194 related articles for article (PubMed ID: 19440565)
41. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
[TBL] [Abstract][Full Text] [Related]
42. Infliximab for Crohn's disease: the first 500 patients followed up through 2009.
Seminerio JL; Loftus EV; Colombel JF; Thapa P; Sandborn WJ
Dig Dis Sci; 2013 Mar; 58(3):797-806. PubMed ID: 23053885
[TBL] [Abstract][Full Text] [Related]
43. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
[TBL] [Abstract][Full Text] [Related]
44. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
[TBL] [Abstract][Full Text] [Related]
45. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T
Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921
[TBL] [Abstract][Full Text] [Related]
46. Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission.
Rutgeerts PJ
Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():9-15; discussion 38. PubMed ID: 10597334
[TBL] [Abstract][Full Text] [Related]
47. Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
Fischer M; Campbell SC; Calley CSJ; Helper DJ; Chiorean MV; Fadda HM
Dig Dis Sci; 2017 Nov; 62(11):3131-3137. PubMed ID: 28986660
[TBL] [Abstract][Full Text] [Related]
48. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
Baert F; Glorieus E; Reenaers C; D'Haens G; Peeters H; Franchimont D; Dewit O; Caenepeel P; Louis E; Van Assche G;
J Crohns Colitis; 2013 Mar; 7(2):154-60. PubMed ID: 22537637
[TBL] [Abstract][Full Text] [Related]
49. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
Da W; Zhu J; Wang L; Lu Y
Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447
[TBL] [Abstract][Full Text] [Related]
50. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
[TBL] [Abstract][Full Text] [Related]
51. [Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab].
Martín De Carpi J; Varea V
An Pediatr (Barc); 2009 Mar; 70(3):271-7. PubMed ID: 19409244
[TBL] [Abstract][Full Text] [Related]
52. [Adalimumab induction and maintenance therapy for Crohn's disease. An open-label study].
López Palacios N; Mendoza JL; Taxonera C; Lana R; Fuentes Ferrer M; Díaz-Rubio M
Rev Esp Enferm Dig; 2008 Nov; 100(11):676-81. PubMed ID: 19159170
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of concomitant elemental diet therapy in scheduled infliximab therapy in patients with Crohn's disease to prevent loss of response.
Kamata N; Oshitani N; Watanabe K; Watanabe K; Hosomi S; Noguchi A; Yukawa T; Yamagami H; Shiba M; Tanigawa T; Watanabe T; Tominaga K; Fujiwara Y; Arakawa T
Dig Dis Sci; 2015 May; 60(5):1382-8. PubMed ID: 25532505
[TBL] [Abstract][Full Text] [Related]
54. Maintenance of remission in Crohn's disease.
Gonvers JJ; Juillerat P; Mottet C; Felley C; Burnand B; Vader JP; Michetti P; Froehlich F
Digestion; 2005; 71(1):41-8. PubMed ID: 15711049
[TBL] [Abstract][Full Text] [Related]
55. Intensification of infliximab therapy in Crohn's disease: efficacy and safety.
M Chaparro ; Martínez-Montiel P; Van Domselaar M; Bermejo F; Pérez-Calle JL; Casis B; Román AL; Algaba A; Maté J; Gisbert JP
J Crohns Colitis; 2012 Feb; 6(1):62-7. PubMed ID: 22261529
[TBL] [Abstract][Full Text] [Related]
56. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
[TBL] [Abstract][Full Text] [Related]
57. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
Rutgeerts P; Feagan BG; Lichtenstein GR; Mayer LF; Schreiber S; Colombel JF; Rachmilewitz D; Wolf DC; Olson A; Bao W; Hanauer SB
Gastroenterology; 2004 Feb; 126(2):402-13. PubMed ID: 14762776
[TBL] [Abstract][Full Text] [Related]
58. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
59. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
